Tfayli Arafat Hussein, Fakhri Ghina Bassam, Al Assaad Majd Sassine
Department of Internal Medicine, Division of Hematology and Oncology, American University of Beirut, Beirut, Lebanon.
Ann Thorac Med. 2019 Jul-Sep;14(3):173-178. doi: 10.4103/atm.ATM_344_18.
Lung cancer remains a major cause of cancer mortality with a 5-year survival in advanced stages around 4%. Platinum-based chemotherapy was routinely used as the standard of care in patients with advanced nonsmall cell lung cancer, but it is being progressively replaced by targeted molecular therapy. One of the molecular aberrations harbored by lung adenocarcinoma is the epidermal growth factor receptor (EGFR). A large ethnic variation has been reported in the prevalence of EGFR mutations in patients with lung adenocarcinoma. Data regarding its prevalence from the Middle East area remains limited. This paper aims at reviewing the data available for the prevalence of this mutation in the Middle Eastern patient population and comparing it with other reported series.
肺癌仍然是癌症死亡的主要原因，晚期患者的5年生存率约为4%。铂类化疗曾是晚期非小细胞肺癌患者的常规标准治疗方法，但它正逐渐被靶向分子疗法所取代。肺腺癌存在的分子异常之一是表皮生长因子受体（EGFR）。据报道，肺腺癌患者中EGFR突变的患病率存在很大的种族差异。中东地区关于其患病率的数据仍然有限。本文旨在回顾中东患者群体中该突变患病率的现有数据，并将其与其他报道的系列进行比较。
